Organon & Co. (NYSE:OGN) Q2 2022 Earnings Conference Call August 4, 2022 8:30 AM ET Company Participants Jennifer Halchak - Vice President, Investor Relations Kevin Ali - Chief Executive Officer Matt Walsh - Chief Financial Officer Sandra Milligan - Head, R&D Conference Call Participants Jason Gerberry - Bank of America Umer Raffat - Evercore David Amsellem - Piper Sandler Greg Fraser - Truist Securities Operator Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone ...

Organon Q2 2022 Earnings · · ORGANON™ Disclaimer statement This text should be viewed in conjunction with Organon's Q2 2022 earnings call Safe Harbor for Forward-Looking Statements Except for historical information herein, this presentation includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about management's expectations about Organon's future financial performance and ...

Organon Q1 2022 Earnings · · ORGANON™ Disclaimer statement This text should be viewed in conjunction with Organon's Q1 2022 earnings call Safe Harbor for Forward-Looking Statements Except for historical information herein, this presentation includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about management's expectations about Organon's future financial performance and ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ Form 10-Q ________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File No. 001-40235 Organon & Co. (Exact name of registrant as specified in its charter) (Ad ...

Organon & Co (NYSE:OGN) Q1 2022 Earnings Conference Call May 5, 2022 8:30 AM ET Company Participants Jennifer Halchak - VP, IR Kevin Ali - CEO & Director Matthew Walsh - EVP & CFO Conference Call Participants Jason Gerberry - Bank of America Merrill Lynch Terence Flynn - Morgan Stanley Eric Musonza - Evercore ISI Chris Shibutani - Goldman Sachs Group David Amsellem - Piper Sandler & Co. Gregory Fraser - Truist Securities Michael Nedelcovych - Cowen and Company Operator Ladies and gentlemen, thank you for st ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ Form 10-K _____________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File No. 001-40235 Organon & Co. (Exact name of registrant as specified in its charter) (State ...

Summary of Organon & Co. Conference Call Company Overview - **Company**: Organon & Co. (NYSE: OGN) [1] - **Event**: 42nd Annual Cowen Health Care Conference [1] Key Points Discussed Industry Focus - The conference primarily centered on the **women's health** sector, highlighting its significance in Organon's product portfolio [4] Product Performance - **NEXPLANON**: - Achieved the highest sales in Q4, marking a record quarter for the product [4] - Management expressed confidence in maintaining this sales level, indicating a new growth trajectory for NEXPLANON [5] Management Insights - **Kevin Ali** (CEO) emphasized the importance of understanding the background of sales growth, suggesting that it was a result of a strategic building process [5] Additional Important Information - The management team included key figures such as the CEO, CFO, Head of R&D, and Head of Investor Relations, indicating a strong leadership presence during the conference [2][3]

Organon & Co. (NYSE:OGN) Q4 2021 Results Conference Call February 17, 2022 8:30 AM ET Company Participants Jennifer Halchak - VP, IR Kevin Ali - CEO Matt Walsh - CFO Conference Call Participants Jason Gerberry - Bank of America Chris Schott - JP Morgan Greg Fraser - Truist Securities Umer Raffat - Evercore ISI Navann Ty - Citi Steve Scala - Cowen David Amsellem - Piper Sandler Operator Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to the Organon Fourth Quart ...

Organon Q4 and Full Year 2021 Earnings ANON™ Disclaimer statement 2 This text should be viewed in conjunction with Organon's Full Year/Q4 2021 earnings call Safe Harbor for Forward-Looking Statements Except for historical information herein, this news release includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about management's expectations about Organon's future financ ...

Organon & Co. (NYSE:OGN) JPMorgan 40th Annual Healthcare Conference Call January 10, 2022 2:15 PM ET Company Participants Kevin Ali - Chief Executive Officer Matt Walsh - Chief Financial Officer Conference Call Participants Chris Schott - JPMorgan Chase & Co. Chris Schott Good afternoon, everybody. I'm Chris Schott at JPMorgan, and it's my pleasure to be hosting a fireside chat with the Organon management team today. From the company, we have Kevin Ali, the company's CFO; [sic] [CEO] as well as Matt Walsh, ...